To evaluate the frequency of acute exacerbations over one year in groups of Cystic Fibrosis patients treated with monthly infusions of (1) serum albumin placebo, (2) low dose (200 mg/kg) MEP IVIG, and (3) high dose (400 mg/kg) MEP IVIG. The safety of monthly MEP IVIG infusions will be determined by comparing the incidence of adverse events among the three study groups.
Showing the most recent 10 out of 945 publications